Dhanuka Agritech Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2025, recommended Final Dividend of Rs. 2 per equity share.
DHANUKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.7 pts more than Nifty Microcap 250 and 11.2 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dhanuka Agritech's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025, with statutory auditors S S Kothari Mehta & Co issuing an unmodified opinion. FY25 revenue from operations rose ~16% YoY to Rs. 2,035 crore, with profit before tax up ~23% to Rs. 392 crore and operating cash flow nearly doubling to Rs. 263 crore. Q4 alone delivered a strong performance, with revenue up ~20% to Rs. 442 crore and PAT of Rs. 75.5 crore, up ~28% YoY. The board recommended a final dividend of Rs. 2 per share (100% on face value) with a record date of July 18, 2025. Other key updates include the completed Rs. 100 crore buyback of 5 lakh shares, the acquisition of international rights to Iprovalicarb and Triadimenol from Bayer AG covering 20+ countries, and the cessation of Independent Director Mr. Siraz Azmat Chaudhary on July 22, 2025.
Strong full-year results, healthy operating cash flow expansion, and a 100% dividend signal financial strength and reward shareholders. The Bayer deal opens a new international growth runway across LATAM, EMEA and Asia, which could be a long-term positive, while the Rs. 100 crore buyback already executed supports EPS and signals capital discipline.